Last Updated : February 14, 2025
Details
FilesGeneric Name:
pertuzumab
Project Status:
Active
Therapeutic Area:
HER2+ breast cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0379-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
In combination with trastuzumab and chemotherapy for early stage HER2+ breast cancer in the neoadjuvant setting.
| Call for patient/clinician/industry input open | 9-Jan-25 |
|---|---|
| Call for patient/clinician/industry input closed | 3-Mar-25 |
| Review initiated | 14-Feb-25 |
| Expert committee meeting (initial) | 17-Jul-25 |
Files
Last Updated : February 14, 2025